Provided by Tiger Trade Technology Pte. Ltd.

MAIA Biotechnology Inc.

1.17
-0.0100-0.85%
Post-market: 1.210.0406+3.47%16:56 EDT
Volume:781.01K
Turnover:921.84K
Market Cap:72.24M
PE:-1.92
High:1.22
Open:1.18
Low:1.15
Close:1.18
52wk High:3.19
52wk Low:0.8700
Shares:61.74M
Float Shares:55.30M
Volume Ratio:1.00
T/O Rate:1.41%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6085
EPS(LYR):-0.7000
ROE:-218.68%
ROA:-92.10%
PB:3.49
PE(LYR):-1.67

Loading ...

Diamond Equity releases update note on MAIA Biotechnology

TIPRANKS
·
Yesterday

MAIA Biotechnology files to sell 751,879 shares of common stock for holders

TIPRANKS
·
Sep 26

Maia Biotechnology - Selling Stockholder Offering 751,879 Shares of Maia Biotechnology Common Stock - SEC Filing

THOMSON REUTERS
·
Sep 26

Maia Biotech Wins Spanish, Portuguese Regulatory Clearance to Screen Patients in THIO-104 Lung Cancer Trial

Reuters
·
Sep 23

Maia Biotechnology Expands Pivotal Phase 3 Thio-104 Non-Small Cell Lung Cancer Trial into Spain and Portugal

THOMSON REUTERS
·
Sep 23

Maia Biotechnology - Targets 100 Patients Dosed in Thio-104 by Year-End 2026; Interim Analysis in 2027

THOMSON REUTERS
·
Sep 23

MAIA Biotechnology Expands Pivotal Phase 3 THIO-104 Non-Small Cell Lung Cancer Trial into Spain and Portugal

GlobeNewswire
·
Sep 23

Maia Biotech Says Phase 3 THIO-104 Trial in Third-Line NSCLC Enrolls 65 Patients

Reuters
·
Sep 22

Maia Biotechnology Reports Pivotal Phase 3 Clinical Trial Progress in Advanced Non-Small Cell Lung Cancer

THOMSON REUTERS
·
Sep 22

MAIA Biotechnology Reports Pivotal Phase 3 Clinical Trial Progress in Advanced Non-Small Cell Lung Cancer

GlobeNewswire
·
Sep 22

Maia Biotechnology Wins $2.3 Million NIH Grant for Phase 2 NSCLC Trial Expansion

Reuters
·
Sep 16

Maia Biotechnology Doses First U.S. Patient in Ongoing Phase 2 Non-Small Cell Lung Cancer Clinical Trial

THOMSON REUTERS
·
Sep 16

MAIA Biotechnology Doses First U.S. Patient in Ongoing Phase 2 Non-Small Cell Lung Cancer Clinical Trial

GlobeNewswire
·
Sep 16

Maia Biotechnology Board Member Ramiro Guerrero Boosts Stake with USD 252,284 Share Buy

Reuters
·
Sep 15

Maia Biotechnology Announces Open Market Purchases of Company Stock by Long-Standing Board Member and CEO

THOMSON REUTERS
·
Sep 15

Maia Biotechnology - Directors and Officers Hold 21.34% Stake as of Sept 14, 2026

THOMSON REUTERS
·
Sep 15

MAIA Biotechnology Announces Open Market Purchases of Company Stock by Long-Standing Board Member and CEO

GlobeNewswire
·
Sep 15

MAIA Biotechnology Director Makes Bold Insider Move With Fresh Stock Purchase

TIPRANKS
·
Sep 15

Maia Biotechnology Director Ramiro Guerrero Acquires 37,595 Common Shares Worth $49,511.38

Reuters
·
Sep 14

MAIA Biotechnology Presents Next-Generation Telomere-Targeting Cancer Drug Candidates at IRT 2026

Reuters
·
Sep 10